Logo image of TKNO

ALPHA TEKNOVA INC (TKNO) Stock Fundamental Analysis

NASDAQ:TKNO - Nasdaq - US02080L1026 - Common Stock - Currency: USD

6.49  -0.16 (-2.41%)

After market: 6.49 0 (0%)

Fundamental Rating

3

TKNO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. TKNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TKNO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

TKNO had negative earnings in the past year.
In the past year TKNO has reported a negative cash flow from operations.
In the past 5 years TKNO reported 4 times negative net income.
In the past 5 years TKNO reported 4 times negative operating cash flow.
TKNO Yearly Net Income VS EBIT VS OCF VS FCFTKNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

TKNO has a worse Return On Assets (-22.52%) than 67.27% of its industry peers.
Looking at the Return On Equity, with a value of -32.46%, TKNO is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -22.52%
ROE -32.46%
ROIC N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
TKNO Yearly ROA, ROE, ROICTKNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

The Gross Margin of TKNO (19.16%) is worse than 83.64% of its industry peers.
In the last couple of years the Gross Margin of TKNO has declined.
The Profit Margin and Operating Margin are not available for TKNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
TKNO Yearly Profit, Operating, Gross MarginsTKNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

5

2. Health

2.1 Basic Checks

TKNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TKNO has more shares outstanding
Compared to 5 years ago, TKNO has more shares outstanding
Compared to 1 year ago, TKNO has a worse debt to assets ratio.
TKNO Yearly Shares OutstandingTKNO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TKNO Yearly Total Debt VS Total AssetsTKNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TKNO has an Altman-Z score of 4.23. This indicates that TKNO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.23, TKNO is doing good in the industry, outperforming 78.18% of the companies in the same industry.
TKNO has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TKNO (0.11) is better than 61.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACCN/A
WACC10.65%
TKNO Yearly LT Debt VS Equity VS FCFTKNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.82 indicates that TKNO has no problem at all paying its short term obligations.
The Current ratio of TKNO (3.82) is comparable to the rest of the industry.
TKNO has a Quick Ratio of 3.21. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TKNO (3.21) is better than 61.82% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.21
TKNO Yearly Current Assets VS Current LiabilitesTKNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

5

3. Growth

3.1 Past

TKNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.27%, which is quite impressive.
The Revenue has been growing slightly by 2.88% in the past year.
The Revenue has been growing by 12.68% on average over the past years. This is quite good.
EPS 1Y (TTM)43.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)2.88%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%17.77%

3.2 Future

The Earnings Per Share is expected to grow by 16.88% on average over the next years. This is quite good.
TKNO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.62% yearly.
EPS Next Y30.27%
EPS Next 2Y16.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y12.41%
Revenue Next 3YN/A
Revenue Next 5Y16.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TKNO Yearly Revenue VS EstimatesTKNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 20M 40M 60M 80M 100M
TKNO Yearly EPS VS EstimatesTKNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TKNO. In the last year negative earnings were reported.
Also next year TKNO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TKNO Price Earnings VS Forward Price EarningsTKNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TKNO Per share dataTKNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

TKNO's earnings are expected to grow with 16.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.88%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

TKNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALPHA TEKNOVA INC

NASDAQ:TKNO (4/25/2025, 8:00:01 PM)

After market: 6.49 0 (0%)

6.49

-0.16 (-2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04 2025-03-04/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners11.93%
Inst Owner Change-87.89%
Ins Owners9.33%
Ins Owner Change0%
Market Cap346.83M
Analysts80
Price Target11.22 (72.88%)
Short Float %23.65%
Short Ratio5.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.29%
Min EPS beat(2)-30.72%
Max EPS beat(2)10.13%
EPS beat(4)3
Avg EPS beat(4)5.03%
Min EPS beat(4)-30.72%
Max EPS beat(4)21.57%
EPS beat(8)6
Avg EPS beat(8)7.02%
EPS beat(12)8
Avg EPS beat(12)-8.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.17%
Min Revenue beat(2)2.17%
Max Revenue beat(2)4.18%
Revenue beat(4)3
Avg Revenue beat(4)3.4%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)7.66%
Revenue beat(8)5
Avg Revenue beat(8)3.98%
Revenue beat(12)9
Avg Revenue beat(12)5.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.12%
PT rev (3m)37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.25%
Revenue NY rev (1m)-2.77%
Revenue NY rev (3m)-2.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.19
P/FCF N/A
P/OCF N/A
P/B 4.21
P/tB 5
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.71
BVpS1.54
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.52%
ROE -32.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.16%
FCFM N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.1%
Cap/Sales 2.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.21
Altman-Z 4.23
F-Score4
WACC10.65%
ROIC/WACCN/A
Cap/Depr(3y)348.43%
Cap/Depr(5y)400.74%
Cap/Sales(3y)30.86%
Cap/Sales(5y)32.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y30.27%
EPS Next 2Y16.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.88%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%17.77%
Revenue Next Year8.97%
Revenue Next 2Y12.41%
Revenue Next 3YN/A
Revenue Next 5Y16.62%
EBIT growth 1Y16.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.13%
EBIT Next 3YN/A
EBIT Next 5Y17.51%
FCF growth 1Y49.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.14%
OCF growth 3YN/A
OCF growth 5YN/A